-

Morganti & Co., Announces that Class Certification Scheduled in the pending shareholder litigation against Auxly Cannabis Group, Inc.

TORONTO--(BUSINESS WIRE)--On January 18, 2023, the shareholders' motion to certify the causes of action and proceeding against Auxly Cannabis Group, Inc. (“XLY”) will be heard. If you purchased Auxly's securities between September 20, 2018 and February 7, 2019, your rights may be affected by the pending motion to certify the causes of action against XLY. You are not required to contribute the financing of the costs associated with this class action. Morganti & Co. is financing the litigation and will be reimbursed if there is a court approved resolution.

On June 16, 2021, the Ontario Superior Court of Justice granted the shareholder's motion to grant leave to proceed with the statutory cause of action found at section 138.3 of the Ontario Securities Act; and on November 11, 2021, the Divisional Court denied XLY's motion to appeal the leave to proceed order.

The shareholders' dispute with Auxly concerns investor documents containing alleged misrepresentations of material fact about the status of the completion date for the renovations being made to the facility in Cobourg, Ontario (the “Facility”) pursuant to the agreement Auxly had with FSD Pharma, Inc. (“HUGE”), as well as misrepresentations Auxly made about the date for planting of first-harvest of cannabis at the Facility.

If you purchased Auxly’s securities after September 20, 2018, you are encouraged to register on our Firm’s informational page found here: https://morgantico.com/auxly-cannabis-group-inc/.

About Morganti & Co. You may learn more about Morganti & Co. online at www.morgantico.com. The Firm also represents investors in litigation against Aphria Inc. (TSX: “APHA”) and Wayland Group Corp. (formerly known as "Maricann") (CSE: “WAYL”). Morganti & Co. also represented investors that purchased shares of FSD Pharma, Inc. that has since been resolved.

This press release may be considered attorney advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Morganti & Co., P.C.
Kristin Swenea
info@morgantico.com

Industry:

Morganti & Co., P.C.

TSX:XLY
Release Versions
English

Contacts

Morganti & Co., P.C.
Kristin Swenea
info@morgantico.com

More News From Morganti & Co., P.C.

Berger Montague (Canada) PC Announces Shareholder Investigation Into Standard Lithium Ltd.

TORONTO--(BUSINESS WIRE)--Berger Montague (Canada) P.C. is announcing that it has been directed by its clients to investigate Standard Lithium Ltd. (“Standard Lithium) (TSX: “SLI” and FRA: “S5L”) concerning its Third Quarter 2023 Results. Standard Lithium held itself out as focused on commercializing its “proprietary” direct lithium extraction process, which the company claimed could achieve the remarkable recovery rate of about 90% of lithium extracted from brine. On November 18, 2021, Blue Or...

Berger Montague (Canada), P.C. Announces Re-investigation Into Previously Published Reports Regarding Reconnaissance Energy Africa, Ltd. Target Price Cut by Over 40% Triggers Investors' Second Investigation

TORONTO--(BUSINESS WIRE)--Berger Montague (Canada) P.C. announces that it has been invited to re-investigate previously published reports about Reconnaissance Energy Africa Ltd. (“ReconAfrica” or the “Company”) (TSXV: RECO; OTCQX: RECAF; and FRA: 0XD). On April 23, 2023, a U.S. federal court denied ReconAfrica's motion to dismiss the U.S. shareholder class action claims and was ordered to file an answer to the complaint that it previously misled investors. After the Company's November 2022, inv...

Siskinds LLP, Merchant Law Group LLP and Siskinds Desmeules, Avocats Announce the Settlement of Invokana®, Invokamet® and/or Invokamet XR®Class Action Litigation

LONDON, Ontario & REGINA, Saskatchewan & QUEBEC CITY--(BUSINESS WIRE)--James Boyd of Siskinds LLP, E.F. Anthony Merchant K.C. of Merchant Law Group, and Chloé Faucher-Lafrance of Siskinds Desmeules, Avocats announce that a Canada-wide settlement has been reached in three class actions relating to the prescription drugs Invokana®, Invokamet®, and Invokamet XR®. The Settlement of the Proceedings has been approved by the Courts. The Defendants deny all allegations and deny any wrongdoing or liabil...
Back to Newsroom